SREBF1 and non-small cell lung carcinoma: Critically, pharmacological targeting of SREBP-1 restored the sensitivity of resistant lung tumor spheroids to lorlatinib and was able to overcome the established CAF-mediated lipid metabolism-supportive niche, highlighting potential new therapeutic options for the clinical treatment of advanced NSCLC.